Back to Results
Ipilimumab, Nivolumab, and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
||A Phase I Study With an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
||Andrew Evens, DO
This phase I trial studies the side effects and best dose of ipilimumab and nivolumab when given together with brentuximab vedotin in treating patients with Hodgkin lymphoma that has returned after a period of improvement or has not responded to previous treatment.
- Must have relapsed or refractory classical Hodgkin lymphoma (cHL)
- Must have relapsed after first line chemotherapy; may have relapsed after autologous or allogeneic stem cell transplant, or have primary refractory disease
- Must have one or more tumors measurable by CT or PET/CT scan
- Must not have previously existing hypersensitivity to brentuximab vedotin or ipilimumab
- Must not have autoimmune disorders or conditions of immunosuppression that require current ongoing treatment
- Must not be participating in any other clinical trial or taking any other experimental medications within 21 days prior to registration
Patients will either receive nivolumab, ipilimumab, or both nivolumab and ipilumab in combination with brentuximab vedotin. Research visits will occur once a cycle (with each cycle being 21 days) for 17 cycles. If subjects are doing well on treatment they may continue the regimen for up to two years. Baseline ECG and CT scan will be performed.